New drug combo shows promise for Hard-to-Treat cancers
NCT ID NCT04752826
First seen Feb 19, 2026 · Last updated May 12, 2026 · Updated 10 times
Summary
This early-stage trial tests a new drug called BI-1808, alone or with another drug (pembrolizumab), in people with advanced cancers (like ovarian cancer, melanoma, or T-cell lymphoma) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. About 176 participants will receive infusions every three weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Byudzhetnoye Uchrezhdeniye Zdravookhraneniya Omskoy Oblasti - Klinicheskiy Onkologicheskiy Dispanser
TERMINATEDOmsk, 644013, Russia
-
City of Hope National Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact
-
Debreceni Egyetem Klinikai Központ
WITHDRAWNDebrecen, 4032, Hungary
-
Guy's and Saint Thomas' NHS Foundation Trust
RECRUITINGLondon, SE1 9RT, United Kingdom
Contact
-
Herlev Hospital
RECRUITINGHerlev, 2730, Denmark
Contact
-
Hospital General Universitario Gregorio Marañon
RECRUITINGMadrid, 28007, Spain
-
Hospital Universitario 12 de Octubre
NOT_YET_RECRUITINGMadrid, 28041, Spain
-
Institut Catala d'oncologia. Hospital Duran I Reynals
NOT_YET_RECRUITINGBarcelona, 08907, Spain
-
Karolinska University Hospital, Solna
RECRUITINGStockholm, 17176, Sweden
Contact
-
Magyar Honvédség-Egészségügyi Központ
RECRUITINGBudapest, 1134, Hungary
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10021, United States
Contact
-
N.N. Petrov National Medical Research Center of Oncology
WITHDRAWNSaint Petersburg, 197758, Russia
-
National Medical Research Center VA Almazov
WITHDRAWNSaint Petersburg, 197022, Russia
-
PRA Health Sciences - Hungary
ACTIVE_NOT_RECRUITINGBudapest, 1077, Hungary
-
Rigshospitalet
RECRUITINGCopenhagen, Denmark
Contact
-
START Madrid - Hospital Universitario Fundación Jiménez Díaz
RECRUITINGMadrid, 28040, Spain
-
Sahlgrenska University Hospital
RECRUITINGGothenburg, 41345, Sweden
Contact
-
Sarah Cannon Research Institute UK
RECRUITINGLondon, W1G 6AD, United Kingdom
Contact
-
Skanes University Hospital
RECRUITINGLund, 223 70, Sweden
Contact
-
Southampton General Hospital
RECRUITINGSouthampton, SO16 6YD, United Kingdom
Contact
-
The Christie NHS Foundation Trust
RECRUITINGManchester, M20 4BX, United Kingdom
Contact
-
The Royal Marsden Hospital NHS Foundation Trust
RECRUITINGLondon, United Kingdom
Contact
-
University Hospital Birmingham
RECRUITINGBirmingham, United Kingdom
Contact
-
University Hospitals of Leicester NHS Trust
RECRUITINGLeicester, LE1 5WW, United Kingdom
Contact
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact
Conditions
Explore the condition pages connected to this study.